Impact of moderate-to-high-suicide-intent in major depressive disorder: a retrospective cohort study on patient characteristics and healthcare resource utilisation in England.


Journal

BMC psychiatry
ISSN: 1471-244X
Titre abrégé: BMC Psychiatry
Pays: England
ID NLM: 100968559

Informations de publication

Date de publication:
23 Aug 2024
Historique:
received: 12 09 2023
accepted: 15 07 2024
medline: 24 8 2024
pubmed: 24 8 2024
entrez: 23 8 2024
Statut: epublish

Résumé

Major depressive disorder (MDD) is a disabling mental illness that can affect all aspects of daily life and is a leading cause of healthcare resource utilisation (HCRU). We aimed to characterise patients with MDD with moderate-to-high-suicide-intent, compare their HCRU to patients with MDD without moderate-to-high-suicide-intent, and better understand their patient pathways. This retrospective cohort study used data collected from primary care electronic health records from Clinical Practice Research Datalink (CPRD), linked to Hospital Episode Statistics, Mental Health Services Data Set, and Office for National Statistics in England. Adults diagnosed with ≥ 1 MDD diagnosis between 04/2007 and 11/2015 were categorised by suicide intent. 307,476 patients with MDD were included (294,259 patients without moderate-to-high-suicide-intent and 13,217 with moderate-to-high-suicide-intent). Patients with MDD with moderate-to-high-suicide-intent were younger on average (39.0 vs. 44.8 years) and included a lower percentage of females (58% vs. 65%) compared to patients without moderate-to-high-suicide-intent. HCRU was greater among patients with moderate-to-high-suicide-intent than patients without moderate-to-high-suicide-intent during the first follow-up year for general practitioner consultations (38.5 vs. 29.4), psychiatric outpatient visits (1.5 vs. 0.1), psychiatrist visits (3.6 vs. 0.3), emergency visits (1.5 vs. 0.3), and hospitalisations (86% vs. 26%). Overall, 56% of patients with moderate-to-high-suicide-intent had an antidepressant prescription within 30 days from the initial moderate-to-high-suicide-intent. Patients with MDD and moderate-to-high-suicide-intent were younger, included more males and incurred greater HCRU than those without moderate-to-high-suicide-intent. These results suggest a greater need for effective medical care and appropriate treatments for patients with moderate-to-high-suicide-intent, which could help reduce associated symptoms, mortality, and HCRU.

Sections du résumé

BACKGROUND BACKGROUND
Major depressive disorder (MDD) is a disabling mental illness that can affect all aspects of daily life and is a leading cause of healthcare resource utilisation (HCRU).
AIMS OBJECTIVE
We aimed to characterise patients with MDD with moderate-to-high-suicide-intent, compare their HCRU to patients with MDD without moderate-to-high-suicide-intent, and better understand their patient pathways.
METHODS METHODS
This retrospective cohort study used data collected from primary care electronic health records from Clinical Practice Research Datalink (CPRD), linked to Hospital Episode Statistics, Mental Health Services Data Set, and Office for National Statistics in England. Adults diagnosed with ≥ 1 MDD diagnosis between 04/2007 and 11/2015 were categorised by suicide intent.
RESULTS RESULTS
307,476 patients with MDD were included (294,259 patients without moderate-to-high-suicide-intent and 13,217 with moderate-to-high-suicide-intent). Patients with MDD with moderate-to-high-suicide-intent were younger on average (39.0 vs. 44.8 years) and included a lower percentage of females (58% vs. 65%) compared to patients without moderate-to-high-suicide-intent. HCRU was greater among patients with moderate-to-high-suicide-intent than patients without moderate-to-high-suicide-intent during the first follow-up year for general practitioner consultations (38.5 vs. 29.4), psychiatric outpatient visits (1.5 vs. 0.1), psychiatrist visits (3.6 vs. 0.3), emergency visits (1.5 vs. 0.3), and hospitalisations (86% vs. 26%). Overall, 56% of patients with moderate-to-high-suicide-intent had an antidepressant prescription within 30 days from the initial moderate-to-high-suicide-intent.
CONCLUSIONS CONCLUSIONS
Patients with MDD and moderate-to-high-suicide-intent were younger, included more males and incurred greater HCRU than those without moderate-to-high-suicide-intent. These results suggest a greater need for effective medical care and appropriate treatments for patients with moderate-to-high-suicide-intent, which could help reduce associated symptoms, mortality, and HCRU.

Identifiants

pubmed: 39180055
doi: 10.1186/s12888-024-05961-3
pii: 10.1186/s12888-024-05961-3
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

576

Informations de copyright

© 2024. The Author(s).

Références

Greenberg PE, Fournier AA, Sisitsky T, Simes M, Berman R, Koenigsberg SH, et al. The economic burden of adults with major depressive disorder in the United States (2010 and 2018). PharmacoEconomics. 2021;39(6):653–65.
doi: 10.1007/s40273-021-01019-4 pubmed: 33950419 pmcid: 8097130
Sobocki P, Jönsson B, Angst J, Rehnberg C. Cost of depression in Europe. J Ment Health Policy Econ. 2006;9(2):87–98.
pubmed: 17007486
Global regional, Global Burden of Disease Study 2019. and national burden of 12 mental disorders in 204 countries and territories, 1990–2019: a systematic analysis for the. The Lancet Psychiatry [Internet]. 2022 Feb 1 [cited 2022 Aug 22];9(2):137–50. https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(21)00395-3/fulltext .
Santomauro DF, Mantilla Herrera AM, Shadid J, Zheng P, Ashbaugh C, Pigott DM et al. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. The Lancet [Internet]. 2021 Nov 6 [cited 2022 Aug 22];398(10312):1700–12. https://www.sciencedirect.com/science/article/pii/S0140673621021437 .
de la Torre JA, Vilagut G, Ronaldson A, Serrano-Blanco A, Martín V, Peters M et al. Prevalence and variability of current depressive disorder in 27 European countries: a population-based study. The Lancet Public Health [Internet]. 2021 Oct 1 [cited 2022 Aug 22];6(10):e729–38. https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(21)00047-5/fulltext .
Patel V, Chisholm D, Parikh R, Charlson FJ, Degenhardt L, Dua T, et al. Addressing the burden of mental, neurological, and substance use disorders: key messages from Disease Control Priorities, 3rd edition. Lancet. 2016;387(10028):1672–85.
National Institute for Health and Care Excellence. Nice guideline: Depression in adults: treatment and management. 2022.
Rizvi SJ, Grima E, Tan M, Rotzinger S, Lin P, McIntyre RS et al. Treatment-Resistant Depression in Primary Care across Canada. Can J Psychiatry [Internet]. 2014 Jul 1 [cited 2022 Aug 22];59(7):349–57. https://doi.org/10.1177/070674371405900702 .
Souery D, Oswald P, Massat I, Bailer U, Bollen J, Demyttenaere K, et al. Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J Clin Psychiatry. 2007;68(7):1062–70.
doi: 10.4088/JCP.v68n0713 pubmed: 17685743
Cai H, Jin Y, Liu S, Zhang Q, Zhang L, Cheung T, et al. Prevalence of suicidal ideation and planning in patients with major depressive disorder: a meta-analysis of observation studies. J Affect Disord. 2021;293:148–58.
doi: 10.1016/j.jad.2021.05.115 pubmed: 34192629
Clinical guide. Assessment of suicide risk in people with depression. [Internet]. Centre for Suicide Research at the University of Oxford.; [cited 2021 Oct 21]. https://www.dpt.nhs.uk/download/2hn1ZTaUXY .
Gabriel FC, de Melo DO, Fráguas R, Leite-Santos NC, Mantovani da Silva RA, Ribeiro E. Pharmacological treatment of depression: a systematic review comparing clinical practice guideline recommendations. PLoS ONE. 2020;15(4):e0231700.
doi: 10.1371/journal.pone.0231700 pubmed: 32315333 pmcid: 7173786
Fu XL, Qian Y, Jin XH, Yu HR, Wu H, Du L et al. Suicide rates among people with serious mental illness: a systematic review and meta-analysis. Psychol Med. 2021;1–11.
Louis Appleby and Nav Kapur and Jennifer Shaw and Isabelle Hunt and Saied Ibrahim and Pauline Turnbull and Lana Bojanić and Cathryn Rodway and Su-Gwan Tham and Nicola Richards and James Burns. National Confidential Inquiry into Suicide and Safety in Mental Health: Annual Report: England, Northern Ireland, Scotland and Wales [Internet]. University of Manchester. 2019 [cited 2019 Oct 21]. https://documents.manchester.ac.uk/display.aspx?DocID=46558 .
Coupland C, Hill T, Morriss R, Arthur A, Moore M, Hippisley-Cox J. Antidepressant use and risk of suicide and attempted suicide or self harm in people aged 20 to 64: cohort study using a primary care database. BMJ [Internet]. 2015 Feb 18 [cited 2022 Aug 22];350:h517. https://www.bmj.com/content/350/bmj.h517 .
Denee T, Kerr C, Ming T, Wood R, Tritton T, Middleton-Dalby C, et al. Current treatments used in clinical practice for major depressive disorder and treatment resistant depression in England: a retrospective database study. J Psychiatr Res. 2021;139:172–8.
doi: 10.1016/j.jpsychires.2021.05.026 pubmed: 34077893
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.
doi: 10.1016/0021-9681(87)90171-8 pubmed: 3558716
Borentain S, Nash AI, Dayal R, DiBernardo A. Patient-reported outcomes in major depressive disorder with suicidal ideation: a real-world data analysis using PatientsLikeMe platform. BMC Psychiatry [Internet]. 2020 Jul 23 [cited 2022 Aug 22];20(1):384. https://doi.org/10.1186/s12888-020-02758-y .
Jaffe DH, Rive B, Denee TR. The burden of suicidal ideation across Europe: a cross-sectional survey in five countries. Neuropsychiatr Dis Treat. 2019;15:2257–71.
doi: 10.2147/NDT.S204265 pubmed: 31496708 pmcid: 6689539
Kontopantelis E, Olier I, Planner C, Reeves D, Ashcroft DM, Gask L et al. Primary care consultation rates among people with and without severe mental illness: a UK cohort study using the Clinical Practice Research Datalink. BMJ Open [Internet]. 2015 Dec 1 [cited 2022 Aug 22];5(12):e008650. https://bmjopen.bmj.com/content/5/12/e008650 .
Bowers L, Jeffery D, Bilgin H, Jarrett M, Simpson A, Jones J. Psychiatric intensive care units: a literature review. Int J Soc Psychiatry. 2008;54(1):56–68.
doi: 10.1177/0020764007082482 pubmed: 18309759
Mars B, Heron J, Gunnell D, Martin RM, Thomas KH, Kessler D. Prevalence and patterns of antidepressant switching amongst primary care patients in the UK. J Psychopharmacol. 2017;31(5):553–60.
doi: 10.1177/0269881117693748 pubmed: 28460603

Auteurs

Tom Denee (T)

Janssen-Cilag Ltd, 50-100 Holmers Farm Way, High Wycombe, Buckinghamshire, HP12 4EG, UK. tdenee@its.jnj.com.

Cicely Kerr (C)

Janssen-Cilag Ltd, 50-100 Holmers Farm Way, High Wycombe, Buckinghamshire, HP12 4EG, UK.

Sarah Richards (S)

Janssen-Cilag Ltd, 50-100 Holmers Farm Way, High Wycombe, Buckinghamshire, HP12 4EG, UK.

Natalie Dennis (N)

Amaris Health Economics and Market Access, 7 Rue de Châteaudun, Paris, 75009, France.

Astrid Foix-Colonier (A)

Amaris Health Economics and Market Access, 7 Rue de Châteaudun, Paris, 75009, France.

Claire Fischer (C)

Amaris Health Economics and Market Access, 7 Rue de Châteaudun, Paris, 75009, France.

Fintan Larkin (F)

Acute Mental Health Services, West London NHS Trust, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH